Lupin’s share price rose in early trade on July 15 after the company received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Dabhasa, Gujarat.
As of 12:08 PM, the shares were trading 1.22% higher at ₹1,819.65 on NSE.
The EIR was issued following an inspection conducted from April 8 to April 12, 2024. The inspection concluded with no observations, giving the facility an inspection classification of “No Action Indicated” (NAI).
This facility is part of Lupin Manufacturing Solutions (LMS), which focuses on the development, manufacture, and sale of Active Pharmaceutical Ingredients and Contract Development and Manufacturing Operations.
TOPICS:
Lupin